Sunlenca kit is a prescription medicine containing Lenacapavir, marketed by Gilead Sciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store bottle and blister packs at 20 °C – 25 °C (68 °F – 77 °F), excursions…
Key facts
- Active ingredient (INN)
- Lenacapavir
- Brand
- Sunlenca
- Dosage form
- Kit
- Packs
- 1 kit
- Marketing authorisation holder
- Gilead Sciences
- Manufacturer
- Gilead Sciences
- Origin register
- US FDA, United States
- Storage
- Store bottle and blister packs at 20 °C – 25 °C (68 °F – 77 °F), excursions permitted to 15 °C – 30 °C (59 °F – 86 °F). Store at 20 °C to 25 °C (68 °F to 77 °F), excursions permitted between 15 °C to 30 °C (59 °F to 86 °F). Dispense and store only in original bottle or blister pack.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AX31 Lenacapavir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 December 2022
- Identifiers
- RxCUI 2625890, 2625896, 2625897 +7DailyMed set ID e5652804-29c4-40d7-aeb2-0142ed2a7b5bNDC 61958-3002, 61958-3005Application NDA215973
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * 1.5 mL in 1 vial | 61958-3002-1 | Gilead Sciences | 22 December 2022 |
| 1 kit in 1 carton * 1.5 mL in 1 vial | 61958-3005-1 | Gilead Sciences | 18 March 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Lenacapavir kit.
Other strengths and forms of Lenacapavir
Clinical summary
Lenacapavir is a human immunodeficiency virus 1 capsid inhibitor indicated in combination with other antiretroviral(s), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1, among other approved uses. MedsAcross supplies Lenacapavir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LenacapavirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sunlenca prescribing information (Gilead Sciences) · U.S. National Library of Medicine, DailyMed
- Sunlenca: European public assessment report (EPAR) · European Medicines Agency
- Yeytuo: European public assessment report (EPAR) · European Medicines Agency
Need Sunlenca kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.